Trial Profile

A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belinostat (Primary) ; Ribociclib (Primary)
Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Male breast cancer; Ovarian cancer; Triple negative breast cancer
Focus Adverse reactions
Acronyms CHARGE

22 Apr 2025 Number of treatment arms have been increased from 1 to 2 by the addition of a new experimental dose expansion arm for the triple negative breast cancer patients.
22 Apr 2025 Planned primary completion date changed from 1 Aug 2024 to 1 Jun 2025.
04 May 2023 Planned End Date changed from 1 Aug 2025 to 1 Aug 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com